We had a busy week in London filming leading haematological oncology experts discuss the latest advances in blood cancer at the European Haematology Association Annual Congress.
There has been a great deal of excitement in myeloma in recent months and we gathered a group of experts to debate recent data presented at both EHA and IMS the previous month. Here Prof Gareth Morgan discusses the role of maintenance therapy across the multiple myeloma (MM) disease spectrum with Prof Antonio Palumbo and Dr Paul Richardson. The group discusses the recently reported Intergroup Phase III Study (CALGB 100104) which demonstrated an overall survival benefit with lenalidomide as continuous therapy for patients with newly diagnosed multiple myeloma following autologous stem cell transplantation.
As prof Morgan stated, these recent advances is great news for patients.
You can see full coverage of EHA on ecancer here.